Drugs / GTS-21
GTS-21
also known as
DMXB-A · 3-(2,4-dimethoxybenzylidene) anabaseine · 3-2, 4 dimethoxybenzylidene anabaseine sustained release · [3-(2,4-dimethoxybenzylidene)-anabaseine dihydrochloride] · Dimethoxbenzylidene anabaseine · Dimethoxybenzylidene anabaseine · DMXB-A-SR
Small molecule targets CHRNA7 via activation
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02458313 | Apr 2016 → Dec 2021 | obesity disorder | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 1 | NCT02111551 | Jun 2015 → May 2016 | autism | University of Colorado, Denver | Terminated | No outcome recorded |
| Phase 1 | NCT00255918 | Mar 2004 → Oct 2005 | schizophrenia | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT01400477 | Jul 2011 → Jun 2015 | schizoaffective disorder, schizophrenia | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 2 | NCT00414622 | Nov 2006 → Apr 2007 | Alzheimer disease | CoMentis | Completed | No outcome recorded |
| Phase 2 | NCT00100165 | Jan 2005 → Jul 2007 | schizophrenia | University of Colorado, Denver | Completed | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02538081 Comparator | Aug 2015 → Aug 2016 | schizophrenia | VA Office of Research and Development | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT00419445 Comparator | Feb 2007 → Jan 2008 | attention deficit-hyperactivity disorder | CoMentis | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02432066 Comparator | Sep → Dec 2018 | nicotine dependence | University of Florida | Withdrawn | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00783068 Comparator | Aug 2008 → Dec 2009 | infectious disease with sepsis | Radboud University Medical Center | Completed | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GTS-21 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00783068 ↗ |
| Known as | 3-(2,4-dimethoxybenzylidene) anabaseine | “DMXB-A \[3-(2,4-dimethoxybenzylidene) anabaseine\] may have positive effects on mental focus” NCT02111551 ↗1“a nicotinic cholinergic agonist, 3-\[2,4-Dimethoxybenzylidene\]anabaseine (DMXB-A)” NCT02538081 ↗ |
| Known as | 3-2, 4 dimethoxybenzylidene anabaseine sustained release | “Experimental Study Drug: 3-2, 4 dimethoxybenzylidene anabaseine sustained release (DMXB-A-SR)” NCT01400477 ↗ |
| Known as | [3-(2,4-dimethoxybenzylidene)-anabaseine dihydrochloride] | “GTS-21, [3-(2,4-dimethoxybenzylidene)-anabaseine dihydrochloride]” NCT00783068 ↗ |
| Known as | Dimethoxbenzylidene anabaseine | “Dimethoxbenzylidene anabaseine (DMXB-A) can stimulate the a7 nicotinic receptor; its advantages include easy oral administration and the lack of dependence-causing effects.” NCT00255918 ↗ |
| Known as | Dimethoxybenzylidene anabaseine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00255918 ↗ |
| Known as | DMXB-A | “BACKGROUND: 3-(2,4-dimethoxybenzylidene)-anabaseine (DMXB-A) is a partial agonist at α7 nicotinic acetylcholine receptors that has been evaluated clinically for treatment of...” PMID 20728875 ↗ Aug 20106“Participants will take active experimental medication (Dimethoxybenzylidene anabaseine (DMXB-A) 75 mg)” NCT00255918 ↗ |
| Known as | DMXB-A-SR | “Experimental Study Drug: 3-2, 4 dimethoxybenzylidene anabaseine sustained release (DMXB-A-SR)” NCT01400477 ↗ |
| Action | Activate | “DMXB-A, a nicotinic agonist that activates alpha(7)-nicotinic receptors” PMID 18381905 ↗ Apr 20081“Neuronal acetylcholine receptor protein alpha-7 subunit agonist” CHEMBL134713 ↗ |
| Modality | Small molecule | — CHEMBL134713 ↗ |
| Route | Oral | “can be taken orally” PMID 18381905 ↗ Apr 2008 |
| Target | CHRNA7 | “Neuronal acetylcholine receptor protein alpha-7 subunit agonist” CHEMBL134713 ↗ |